The Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically Ill Infants and Children

32Citations
Citations of this article
68Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Extracorporeal membrane oxygenation (ECMO) support is an established lifesaving therapy for potentially reversible respiratory or cardiac failure. In 10% of all pediatric patients receiving ECMO, ECMO therapy is initiated during or after cardiopulmonary resuscitation. Therapeutic hypothermia is frequently used in children after cardiac arrest, despite the lack of randomized controlled trials that show its efficacy. Hypothermia is frequently used in children and neonates during cardiopulmonary bypass (CPB). By combining data from pharmacokinetic studies in children on ECMO and CPB and during hypothermia, this review elucidates the possible effects of hypothermia during ECMO on drug disposition. © 2012 Elsevier Inc.

Cite

CITATION STYLE

APA

Wildschut, E. D., van Saet, A., Pokorna, P., Ahsman, M. J., Van den Anker, J. N., & Tibboel, D. (2012). The Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically Ill Infants and Children. Pediatric Clinics of North America. W.B. Saunders. https://doi.org/10.1016/j.pcl.2012.07.013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free